iGlarLixi CGM Study in Chinese T2D Individuals After OADs
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 678 participants.
Also called NCT06671587
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 678 participants
- Sponsor
- Registry
-
NCT06671587 -
U1111-1306-6660
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06671587. Randomized; no masking; primary purpose treatment. Start 2024-12-10 (actual); primary completion 2026-09-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs
- Acronym
- China Soli-CGM
- Condition
- Type 2 Diabetes (T2D)
- Intervention (Drug)
- iGlarLixi (insulin glargine/lixisenatide)
- Intervention (Drug)
- Gla-100 (insulin glargine)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct06671587- Content hash
f9e60215e0bdb291d40d16fdb1fa75cc16c956cbdedab397787357c02b92f749